Advertisement

The Scientist

» patent

Most Recent

image: Another Gene-Editing IPO

Another Gene-Editing IPO

By | April 12, 2016

Intellia Therapeutics, which seeks to develop CRISPR-based technologies to target rare diseases, is hoping to raise $120 million in an initial public offering.

0 Comments

image: CRISPR Patent Investigation to Begin

CRISPR Patent Investigation to Begin

By | March 9, 2016

The US Patent and Trademark Office is set to launch its “patent interference” inquiry into the competing patents on the gene-editing technology.

0 Comments

image: New CRISPR Patent Issued

New CRISPR Patent Issued

By | February 18, 2016

Caribou Biosciences receives a patent related to the gene-editing technology.

0 Comments

image: “Heroes of CRISPR” Disputed

“Heroes of CRISPR” Disputed

By | January 19, 2016

Critics have harsh words for the Broad Institute’s Eric Lander and Cell over a recent perspective piece describing the history of CRISPR.

10 Comments

image: Who Owns CRISPR, Cont’d

Who Owns CRISPR, Cont’d

By | January 14, 2016

The US Patent and Trademark Office declares a patent “interference” and will seek to determine who has rights to the gene-editing technology.

1 Comment

image: TS Picks: CRISPR Patent Edition

TS Picks: CRISPR Patent Edition

By | January 5, 2016

A challenge to the first CRISPR patent just got teeth.

3 Comments

image: Who Owns CRISPR?

Who Owns CRISPR?

By | April 3, 2015

With one US patent awarded and many other applications under consideration for the popular genome-editing technology, companies are adopting multiple strategies to navigate the complex intellectual property landscape.

6 Comments

American universities top a list of educational institutions ranked according to their number of international patent applications.

0 Comments

image: Myriad Settles Suit

Myriad Settles Suit

By | January 26, 2015

The Utah-based firm has settled its lawsuit claiming patent infringement against Pathway Genomics.

0 Comments

image: Merck Buys Cubist for $8.4B

Merck Buys Cubist for $8.4B

By | December 11, 2014

Hours after the pharmaceutical giant announced the acquisition, a federal judge invalidated key patents behind the antibiotic maker’s most lucrative product.

0 Comments

Advertisement

Popular Now

  1. LabQuiz: What's Your Cell IQ?
    Sponsored Quiz LabQuiz: What's Your Cell IQ?

    Your body is made up of trillions of cells—but what do you really know about them? Take our lab quiz and determine your CIQ (cell identification quotient). 

  2. Antibody Maker Loses License Over Animal Welfare Violations
  3. Immune Defect Detected in Knockout Mice
  4. Exploring Emotional Contagion
Advertisement
SomaLogic
SomaLogic
Advertisement
Biosearch Technologies
illumina Corporate
illumina Corporate